

### Company Overview

Abeona Therapeutics is focused on developing and delivering gene therapy products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company's close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Epidermolysis Bullosa, Sanfilippo syndrome, Batten disease, and other rare disorders.

### Abeona Therapeutics Details Pathway for Advancing Lead Clinical Programs and Unveils New Cystic Fibrosis Program Born from Next Generation AIM™ Vector Platform at 2018 R&D Day

Dec 6 2018, 12:30 PM EST

### Abeona Therapeutics to Host R&D Day on December 6, 2018

Nov 29 2018, 8:45 AM EST

### Abeona Therapeutics Announces CEO Transition

Nov 26 2018, 4:30 PM EST

### Stock Overview

Symbol	ABEO
Exchange	Nasdaq
Market Cap	431.98m
Last Price	\$9.01
52-Week	\$6.94 - \$22.00

12/10/2018 04:00 PM EST

### Investor Relations

Christine Silverstein  
Senior Vice President, Finance & Investor Relations  
T: +1 (646) 813-4707  
[csilverstein@abeonatherapeutics.com](mailto:csilverstein@abeonatherapeutics.com)

### Management Team

#### João Siffert, MD

Interim Chief Executive Officer, Head of Research & Development and Chief Medical Officer

#### Timothy J. Miller, PhD

President & Chief Scientific Officer

#### Max Colao

Chief Commercial Officer

#### Kaye Spratt, PhD

Senior Vice President, Regulatory Affairs

#### Juan Ruiz, MD, PhD

Head of European Medical Affairs

#### Christine Silverstein

Senior Vice President, Finance & Investor Relations

#### Neena Patil

Senior Vice President, General Counsel and Corporate Secretary

#### Jay Bircher

Senior Vice President, Quality & Technical Operations

#### Edward Carr

Chief Accounting Officer

### Abeona Therapeutics, Inc.

1330 Avenue of the Americas  
33rd Floor  
New York, NY 10019

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.